{"id":"W4387811428","doi":"10.1016/j.annonc.2023.09.1887","title":"701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Institut Gustave-Roussy; Genentech; BeiGene; Eisai Canada; Centre Léon Bérard; Daiichi Sankyo Europe; Servier; Basilea Pharmaceutica; Eisai; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Clovis Oncology; Boston Pharmaceuticals; F. Hoffmann-La Roche; Chugai Pharmaceutical; Agios Pharmaceuticals; Roche; Amgen","keywords":"Medicine; PTEN; Nivolumab; Internal medicine; Oncology; KRAS; Cancer research; Colorectal cancer; Cancer; PI3K/AKT/mTOR pathway; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008487623,0.0012126,0.001154775,0.0003414396,0.0004414961,0.001293046,0.0007374282,0.0007923159,0.004382832],"category_scores_gemma":[0.0005069289,0.0003402455,0.0009700601,0.0003880126,0.0005878754,0.0006554527,0.0004787664,0.003008571,0.001254056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001883846,"about_ca_system_score_gemma":0.00203308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003060631,"about_ca_topic_score_gemma":0.01339353,"domain_scores_codex":[0.9997539,0.000081141,0.000008575106,0.000047445,0.00003304417,0.00007596621],"domain_scores_gemma":[0.9997366,0.00002443659,0.00003326683,0.00001662094,0.00001733237,0.0001717915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4608821,0.03902889,0.01556584,0.001083422,0.003519405,0.0004613563,0.0003850349,0.006695685,0.05841259,0.001621433,0.04651701,0.3658273],"study_design_scores_gemma":[0.643831,0.2667351,0.03975527,0.0001458403,0.001794581,0.0009960257,0.0002468821,0.006977155,0.008631002,0.001293022,0.02948055,0.0001135187],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983886,0.002927538,0.0004853432,0.00197499,0.0003363834,0.00104467,0.002172779,0.0003287357,0.006843594],"genre_scores_gemma":[0.9800274,0.002373225,0.001633611,0.002035725,0.0001706305,0.001213618,0.00564518,0.00006920913,0.006831447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004382832,"threshold_uncertainty_score":0.01466197,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01749602678240846,"score_gpt":0.3275702954259067,"score_spread":0.3100742686434982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}